Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q1 2024

Q1 2024 biggest moves
  • BNTXBNTX

    BioNTech

    New

    0.9% of portfolio

  • BAXBAX

    Baxter International

    Cut 99.5%

    now 0.0% of portfolio

  • SWTXSWTX

    SPRINGWORKS THERAPEUTICS

    Cut 50%

    now 1.1% of portfolio

  • ISRISR

    PERSPECTIVE THERAPEUTICS

    New

    0.6% of portfolio

417 changes in all

Top Holdings367 positions

Checking export access…
Activity:
NUVL
NUVLDelisted

NUVALENT INC

20M$1.5B26.1%——
11 qtrssince 2021-Q3
Unchanged
0
VTRS

Viatris Inc.

21.4M$255.5M4.4%$11.22-4.00%
14 qtrssince 2020-Q4
Increased
61
CNC

Centene Corporation

2.4M$186.9M3.3%$68.16+15.14%
18 qtrssince 2019-Q4
Increased
66
LRMR

Larimar Therapeutics, Inc.

21.2M$161.2M2.8%$6.64+14.32%
16 qtrssince 2020-Q2
Increased
64
161.9M$158.4M2.8%——
6 qtrssince 2022-Q4
Increased
58
AHCO

AdaptHealth Corp.

13.3M$152.6M2.7%$18.05-36.22%
18 qtrssince 2019-Q4
Decreased
0
CPRX
CPRXDelisted

CATALYST PHARMACEUTICALS INC

9.1M$145.5M2.5%——
7 qtrssince 2022-Q3
Increased
53
OSCR

Oscar Health, Inc.

9.4M$139.4M2.4%$9.15+62.51%
2 qtrssince 2023-Q4
Decreased
0
FUSN
FUSNDelisted

FUSION PHARMACEUTICALS INC

6.4M$136.5M2.4%——
5 qtrssince 2023-Q1
Unchanged
0
ACH

Accendra Health, Inc.

4.9M$135.2M2.4%$16.50+67.96%
6 qtrssince 2022-Q4
Decreased
0
??
INSMED INCDelisted
Bond
117M$124.4M2.2%——
17 qtrssince 2020-Q1
Unchanged
0
MRUS
MRUSDelisted

MERUS N V

2.6M$119.3M2.1%——
10 qtrssince 2021-Q4
Decreased
0
??
ACCOLADE INCDelisted
Bond
132.6M$117.5M2.0%——
8 qtrssince 2022-Q2
Unchanged
0
KURA

Kura Oncology, Inc.

5.4M$115.4M2.0%$14.13+50.94%
12 qtrssince 2021-Q2
Increased
52
IDYA

IDEAYA Biosciences, Inc.

2.6M$115.4M2.0%$19.47+125.33%
7 qtrssince 2022-Q3
Unchanged
0
SPRY

ARS Pharmaceuticals, Inc.

11.1M$113.2M2.0%$8.53+19.81%
6 qtrssince 2022-Q4
Unchanged
0
BKD

Brookdale Senior Living Inc.

15.6M$103.2M1.8%$4.41+49.87%
18 qtrssince 2019-Q4
Increased
50
RVMD

Revolution Medicines, Inc.

3.1M$99.6M1.7%$26.00+23.97%
17 qtrssince 2020-Q1
Unchanged
0
103.2M$98.7M1.7%——
1 qtr
New
68
NBIX

Neurocrine Biosciences, Inc.

691,004$95.3M1.7%$95.92+43.78%
13 qtrssince 2021-Q1
Decreased
0
$5.7B
AUM
367
Positions
Q1 2024
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2022-Q4$4,831,008,337-3.83641794758%
2023-Q1$4,485,670,170-7.14836619832%
2023-Q2$4,684,196,2414.42578396262%
2023-Q3$4,538,793,245-3.10411836992%
2023-Q4$5,415,638,75919.3189129063%
2024-Q1$5,748,069,8946.13835504533%
Activity profile
$ moved · Q1'24
New26%Increased19%Decreased16%Exited38%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.7 quarters
<1Q55%1-4Q24%1-2Y3%2Y+18%

Deerfield Management Company, L.P. manages $5.7B across 367 positions as of Q1 2024. Top holdings: NUVL (26.1%), VTRS (4.4%), CNC (3.3%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$6B
NUVL26.12%
VTRS4.44%
CNC3.25%
LRMR2.80%
BROOKDALE SR2.76%
AHCO2.65%
CPRX2.53%
OSCR2.42%
FUSN2.37%
ACH2.35%
Other2.16%

Portfolio allocation by GICS sector

Sectors11
Healthcare90.29%
Unknown8.25%
Technology0.33%
Consumer Cyclical0.28%
Industrials0.27%
Financial Services0.26%
Consumer Defensive0.10%
Communication Services0.06%
Basic Materials0.06%
Real Estate0.06%
Other0.04%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used